Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics, Inc. (DE:2090)
:2090
2090 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.74 - €4.74
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€302.49M
Enterprise Value€393.28M
Total Cash (Recent Filing)$15.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
May 08, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding56,434,220
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
€23.84Price Target Upside402.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Astria Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAstria has begun its Phase 3 ALPHA-ORBIT trial of navenibart in HAE patients, which is progressing on schedule and expected to support approval in the U.S., EU, and Japan.
Efficacy And SafetyThe Phase 3 trial is considered de-risked due to the impressive data from the Phase 1b/2 ALPHA-STAR trial, showing rapid and sustained reductions in HAE attacks.
Bears Say
Market CompetitionTakhzyro, the market leader, generated significant revenue growth, indicating a strong demand for prophylaxis treatments like navenibart.
---
Options Prices
Currently, No data available
---
Ownership Overview
11.96% Insiders
18.51% Mutual Funds
0.02% Other Institutional Investors
59.21% Public Companies and Individual Investors
2090 FAQ
What was Astria Therapeutics, Inc.’s price range in the past 12 months?
Astria Therapeutics, Inc. lowest stock price was €4.74 and its highest was €4.74 in the past 12 months.
What is Astria Therapeutics, Inc.’s market cap?
Astria Therapeutics, Inc.’s market cap is €302.49M.
When is Astria Therapeutics, Inc.’s upcoming earnings report date?
Astria Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 57 days.
How were Astria Therapeutics, Inc.’s earnings last quarter?
Astria Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -€0.404 earnings per share for the quarter, beating the consensus estimate of -€0.406 by €0.002.
Is Astria Therapeutics, Inc. overvalued?
According to Wall Street analysts Astria Therapeutics, Inc.’s price is currently Undervalued.
Does Astria Therapeutics, Inc. pay dividends?
Astria Therapeutics, Inc. does not currently pay dividends.
What is Astria Therapeutics, Inc.’s EPS estimate?
Astria Therapeutics, Inc.’s EPS estimate is -0.43.
How many shares outstanding does Astria Therapeutics, Inc. have?
Astria Therapeutics, Inc. has 56,434,220 shares outstanding.
What happened to Astria Therapeutics, Inc.’s price movement after its last earnings report?
Astria Therapeutics, Inc. reported an EPS of -€0.404 in its last earnings report, beating expectations of -€0.406. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Astria Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:2090
---
Astria Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.84 (402.94% Upside)
€23.84 (402.94% Upside)
Blogger Sentiment
Bullish
DE:2090 Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.47%
12-Months-Change
Fundamentals
Return on Equity
-38.03%
Trailing 12-Months
Asset Growth
86.55%
Trailing 12-Months
Company Description
Astria Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
---
2090 Stock 12 Month Forecast
Average Price Target
€23.84
▲(402.94% Upside)
Technical Analysis
Sangamo Biosciences
―
ProQR
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering 2090
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+16.02%
reiterated a buy rating 7 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +16.02% per trade.
---